CINC News and Press, CinCor Pharma Inc. From 01/09/23

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: Roland Magnusson / Shutterstock.com CinCor (NASDAQ: CINC ) stock is rocketing higher on Monday following news that AstraZeneca (NASDAQ: AZN ) is acquiring the company. The offer from AstraZeneca has ...

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Source: oneinchpunch/Shutterstock.com We’re starting off the week with a look at the biggest pre-market stock movers traders need to know about on Monday! Moving stocks this morning are acquisition deals, clinica...

AstraZeneca ( NASDAQ: AZN ) is acquiring Waltham, Ma.-based high blood pressure and kidney disease drug developer CinCor Pharma ( NASDAQ: CINC ) in a deal value of up to $1.8B. The British pharma giant said that the acquisition will bolster its cardiorenal pipeline by...

WALTHAM, Mass., Jan. 09, 2023 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that it has entered into a definitive agreement with AstraZeneca under which AstraZeneca has agreed to acquire CinCor. Marc de Garidel, Chief Executive Officer at CinCor, said: “We ar...

Summary US biotech stocks topped the list of dissatisfied shareholders in the worst-performing US healthcare sector, and not just because of market headwinds. Among disappointing biotech stocks, CinCor Pharma, Inc., a US biotech developer of a high blood pressure product candidate, miss...

Primary endpoint in Intention to Treat (ITT) was not met despite large absolute reductions in Systolic Blood Pressure (SBP) 12.6 mmHg placebo-adjusted reduction in SBP with 2 mg baxdrostat in a pre-specified subgroup that represents approximately 81-89% of the U.S. hypertension ...

WALTHAM, Mass., Nov. 22, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will present at the following investor conferences in November: The CinCor management team will participate in one-on-one investor meetings during these events....

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- CinCor Pharma, Inc. (NASDAQ: CINC) today announced that company management will participate at the Jefferies London Healthcare Conference taking place on November 15-17, 2022 in London, United Kingdom. The presentation information is below: ...

Aldosterone and renin biomarker activity clinically demonstrate how baxdrostat mechanistically achieves selective blood pressure lowering effects with no impact on cortisol 20.3 mmHg reduction in systolic blood pressure, or 11 mmHg (p-value < 0.0001) placebo-adjusted decline ...

Clinically significant and dose-dependent reduction in blood pressure with baxdrostat Highly selective mechanism of action with no meaningful impact on cortisol supports first-in-class potential Potential treatment for the 10-12 million patients in the US alone with trea...